News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Ranbaxy Laboratories (RANBAXY.BO) Whistleblower and the Scheme to Fool the FDA



5/16/2013 7:48:26 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Earlier this week, the feds finally reached closure with Ranbaxy Laboratories with a $500 million deal to settle criminal and civil charges for a serious and widespread manufacturing ruse. The generic drugmaker was charged with using raw chemicals from unapproved sources, fabricating in-house test data to meet FDA standards and concealing these activities from FDA inspectors by falsifying records. In short, there was a systemic cover-up that Ranbaxy perpetuated for nearly a decade in order to boost profits and maintain its edge as a leading purveyor of low-cost generics to the world. Scientists were ordered to manipulate reports; other employees were forced to illegally carry supplies of brand-name drugs to India and duplicitous statements were issued by high-ranking executives. All the while, ceo Malvinder Singh (pictured), a grandson of the founder, screamed for more profits.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaLive


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES